GeoVax Labs (GOVX) S-1 4 Feb 22 2021 Q3 IPO registration Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Sep. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0000832489
Entity Registrant Name	GeoVax Labs, Inc.
Amendment Flag	false
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	S-1
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0455038
Entity Address, Address Line One	1900 Lake Park Drive, Suite 380
Entity Address, City or Town	Smyrna
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30080
City Area Code	678
Local Phone Number	384-7220
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
ASSETS
Cash and cash equivalents	$ 18,107,019			$ 9,883,796				$ 283,341
Grant funds and other receivables	0			182,663				68,603
Prepaid expenses and other current assets	52,818			168,689				95,320
Total current assets	18,159,837			10,235,148				447,264
Property and equipment, net (Note 3)	168,653			147,741				10,606
Deposits	11,010			11,010				11,010
Total assets	18,339,500			10,393,899				468,880
Current liabilities:
Accounts payable	289,438			267,702				152,653
Accrued expenses (Note 4)	46,212			359,281				1,851,040
Current portion of notes payable	0			183,326				12,500
Total current liabilities	335,650			810,309				2,016,193
Note payable, net of current portion	0			14,738				27,243
Total liabilities	335,650			825,047				2,043,436
Commitments (Note 7)
Stockholders’ equity (deficiency):
Preferred stock, $.01 par value (Note 8): Authorized shares – 10,000,000 Issued and outstanding shares – 100 and 2,486 at December 31, 2020 and 2019, respectively	0			76,095				1,932,433
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 3,834,095 and 14,992 at December 31, 2020 and 2019, respectively	6,382			3,834				15
Additional paid-in capital	68,630,363			55,294,504				39,340,509
Accumulated deficit	(50,632,895)			(45,805,581)				(42,847,513)
Total stockholders’ equity (deficiency)	18,003,850	$ 19,458,338	$ 20,651,340	9,568,852	$ 10,813,744	$ (1,849,621)	$ (1,864,250)	(1,574,556)	$ (1,022,347)
Total liabilities and stockholders’ equity (deficiency)	$ 18,339,500			$ 10,393,899				$ 468,880

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)		10,000,000	10,000,000
Preferred stock, shares issued (in shares)		100	2,486
Preferred stock, shares outstanding (in shares)		100	2,486
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, authorized (in shares)	600,000,000	600,000,000	600,000,000
Common stock, issued (in shares)	6,381,541	3,834,095	14,992
Common stock, outstanding (in shares)	6,381,541	3,834,095	14,992
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	100
Preferred stock, shares outstanding (in shares)	0	100	100

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Grant and collaboration revenue	$ 30,414			$ 415,458			$ 220,539	$ 1,572,037	$ 1,823,658	$ 1,175,896
Operating expenses:
Research and development	1,224,362			416,756			2,659,980	1,687,113	2,444,459	1,910,715
General and administrative	757,432			435,013			2,562,641	1,364,650	2,196,014	1,637,674
Total operating expenses	1,981,794			851,769			5,222,621	3,051,763	4,640,473	3,548,389
Loss from operations	(1,951,380)			(436,311)			(5,002,082)	(1,479,726)	(2,816,815)	(2,372,493)
Other income (expense):
Interest income	877			90			3,998	902	2,271	6,359
Interest expense	0			(134,427)			(1,286)	(142,722)	(143,524)	(4,495)
Gain on debt extinguishment	0			0			172,056	0
Total other income (expense)	877			(134,337)			174,768	(141,820)	(141,253)	1,864
Net loss	$ (1,950,503)	$ (1,314,033)	$ (1,562,778)	$ (570,648)	$ (455,204)	$ (595,694)	$ (4,827,314)	$ (1,621,546)	$ (2,958,068)	$ (2,370,629)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (0.31)			$ (0.73)			$ (0.80)	$ (2.85)	$ (2.14)	$ (781.87)
Weighted average shares outstanding (in shares)	6,349,297			782,978			6,005,032	569,955	1,383,829	3,032

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)	Warrants Issued in Bridge Financing [Member]Preferred Stock [Member]	Warrants Issued in Bridge Financing [Member]Common Stock [Member]	Warrants Issued in Bridge Financing [Member]Additional Paid-in Capital [Member]	Warrants Issued in Bridge Financing [Member]Retained Earnings [Member]	Warrants Issued in Bridge Financing [Member]	Warrant Issued for Technology License[Member]Preferred Stock [Member]	Warrant Issued for Technology License[Member]Common Stock [Member]	Warrant Issued for Technology License[Member]Additional Paid-in Capital [Member]	Warrant Issued for Technology License[Member]Retained Earnings [Member]	Warrant Issued for Technology License[Member]	Conversion from Convertible Debentures to Conversion Units [Member]Preferred Stock [Member]	Conversion from Convertible Debentures to Conversion Units [Member]Common Stock [Member]	Conversion from Convertible Debentures to Conversion Units [Member]Additional Paid-in Capital [Member]	Conversion from Convertible Debentures to Conversion Units [Member]Retained Earnings [Member]	Conversion from Convertible Debentures to Conversion Units [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018																3,450	11
Balance at Dec. 31, 2018																$ 1,971,333	$ 0	$ 37,483,204	$ (40,476,884)	$ (1,022,347)
Issuance of common stock for services (in shares)																0	162			162
Issuance of common stock for services																$ 0	$ 0	24,000	0	$ 24,000
Stock option expense																0	0	104,420	0	104,420
Net loss																$ 0	$ 0	0	(2,370,629)	(2,370,629)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)																1,700	0
Sale of convertible preferred stock for cash and cancellation of note payable																$ 1,542,950	$ 0	147,050	0	1,690,000
Conversion of preferred stock to common stock (in shares)																(2,664)	14,819
Conversion of preferred stock to common stock																$ (1,581,850)	$ 15	1,581,835	0	0
Balance (in shares) at Dec. 31, 2019																2,486	14,992
Balance at Dec. 31, 2019																$ 1,932,433	$ 15	39,340,509	(42,847,513)	(1,574,556)
Issuance of common stock for services (in shares)																0	521
Issuance of common stock for services																$ 0	$ 1	5,999	0	6,000
Net loss																			(595,694)	(595,694)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)																300
Sale of convertible preferred stock for cash and cancellation of note payable																$ 300,000				300,000
Conversion of preferred stock to common stock (in shares)																(2,386)	674,067
Conversion of preferred stock to common stock																$ (1,856,338)	$ 674	1,855,664
Balance (in shares) at Mar. 31, 2020																400	689,580
Balance at Mar. 31, 2020																$ 376,095	$ 690	41,202,172	(43,443,207)	(1,864,250)
Balance (in shares) at Dec. 31, 2019																2,486	14,992
Balance at Dec. 31, 2019																$ 1,932,433	$ 15	39,340,509	(42,847,513)	(1,574,556)
Net loss																				(1,621,546)
Balance (in shares) at Sep. 30, 2020																100	3,559,473
Balance at Sep. 30, 2020																$ 76,095	$ 3,559	55,203,149	(44,469,059)	10,813,744
Balance (in shares) at Dec. 31, 2019																2,486	14,992
Balance at Dec. 31, 2019																$ 1,932,433	$ 15	39,340,509	(42,847,513)	(1,574,556)
Sale of common stock for cash (in shares)																0	2,310,000
Sale of common stock for cash																$ 0	$ 2,310	11,156,186	0	$ 11,158,496
Common stock issued (in shares)																0	286,902			36,902
Issuance of common stock upon warrant exercise																$ 0	$ 287	2,213	0	$ 2,500
Issuance of common stock for services (in shares)																0	26,581			26,581
Issuance of common stock for services																$ 0	$ 27	94,373	0	$ 94,400
Stock option expense																0	0	18,730	0	18,730
Net loss																0	0	0	(2,958,068)	(2,958,068)
Warrants issued in bridge financing																$ 0	$ 0	457,833	0	457,833
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)																300	0
Sale of convertible preferred stock for cash and cancellation of note payable																$ 300,000	$ 0	0	0	300,000
Conversion of preferred stock to common stock (in shares)																(2,686)	716,790
Conversion of preferred stock to common stock																$ (2,156,338)	$ 717	2,155,621	0	0
Common stock issued for cancellation of accrued compensation (in shares)																0	300,001
Issuance of common stock upon cancellation of accrued compensation																$ 0	$ 300	1,499,700	0	1,500,000
Balance (in shares) at Dec. 31, 2020																100	3,834,095
Balance at Dec. 31, 2020																$ 76,095	$ 3,834	55,294,504	(45,805,581)	9,568,852
Balance (in shares) at Mar. 31, 2020																400	689,580
Balance at Mar. 31, 2020																$ 376,095	$ 690	41,202,172	(43,443,207)	(1,864,250)
Issuance of common stock for services (in shares)																0	2,124
Issuance of common stock for services																$ 0	$ 2	11,998	0	12,000
Net loss																$ 0	$ 0	0	(455,204)	(455,204)
Warrants issued in bridge financing	$ 0	$ 0	$ 457,833	$ 0	$ 457,833
Balance (in shares) at Jun. 30, 2020																400	691,704
Balance at Jun. 30, 2020																$ 376,095	$ 692	41,672,003	(43,898,411)	(1,849,621)
Sale of common stock for cash (in shares)																0	2,310,000
Sale of common stock for cash																$ 0	$ 2,310	11,156,186	0	11,158,496
Common stock issued (in shares)																0	36,902
Issuance of common stock for services (in shares)																0	517
Issuance of common stock for services																$ 0	$ 0	6,000	0	6,000
Net loss																$ 0	$ 0	0	(570,648)	(570,648)
Conversion of preferred stock to common stock (in shares)											0	177,626				(300)	42,723
Conversion of preferred stock to common stock											$ 0	$ 177	$ 569,340	$ 0	$ 569,517	$ (300,000)	$ 43	299,957	0	0
Warrants exercised for common stock																$ 0	$ 37	(37)	0	0
Common stock issued for cancellation of accrued compensation (in shares)																0	300,001
Issuance of common stock upon cancellation of accrued compensation																$ 0	$ 300	1,499,700	0	1,500,000
Balance (in shares) at Sep. 30, 2020																100	3,559,473
Balance at Sep. 30, 2020																$ 76,095	$ 3,559	55,203,149	(44,469,059)	10,813,744
Balance (in shares) at Dec. 31, 2020																100	3,834,095
Balance at Dec. 31, 2020																$ 76,095	$ 3,834	55,294,504	(45,805,581)	9,568,852
Sale of common stock for cash (in shares)																0	1,644,000
Sale of common stock for cash																$ 0	$ 1,644	9,407,276	0	9,408,920
Common stock issued (in shares)																0	835,900
Issuance of common stock upon warrant exercise																$ 0	$ 836	3,173,320	0	3,174,156
Issuance of common stock for services (in shares)																0	1,472
Issuance of common stock for services																$ 0	$ 1	5,999	0	6,000
Stock option expense																		56,190		56,190
Net loss																			(1,562,778)	(1,562,778)
Balance (in shares) at Mar. 31, 2021																100	6,315,467
Balance at Mar. 31, 2021																$ 76,095	$ 6,315	67,937,289	(47,368,359)	20,651,340
Balance (in shares) at Dec. 31, 2020																100	3,834,095
Balance at Dec. 31, 2020																$ 76,095	$ 3,834	55,294,504	(45,805,581)	$ 9,568,852
Issuance of common stock for services (in shares)																				13,707
Net loss																				$ (4,827,314)
Balance (in shares) at Sep. 30, 2021																0	6,381,541
Balance at Sep. 30, 2021																$ 0	$ 6,382	68,630,363	(50,632,895)	18,003,850
Balance (in shares) at Mar. 31, 2021																100	6,315,467
Balance at Mar. 31, 2021																$ 76,095	$ 6,315	67,937,289	(47,368,359)	20,651,340
Issuance of common stock for services (in shares)																0	12,235
Issuance of common stock for services																$ 0	$ 13	65,828	0	65,841
Stock option expense																0	0	56,190	0	56,190
Net loss																$ 0	$ 0	0	(1,314,033)	(1,314,033)
Repurchase of preferred stock (in shares)																(100)	0
Repurchase of preferred stock																$ (76,095)	$ 0	75,095	0	(1,000)
Balance (in shares) at Jun. 30, 2021																0	6,327,702
Balance at Jun. 30, 2021																$ 0	$ 6,328	68,134,402	(48,682,392)	19,458,338
Common stock issued (in shares)																0	53,839
Issuance of common stock upon warrant exercise																$ 0	$ 54	229,946	0	230,000
Stock option expense																0	0	56,190	0	56,190
Net loss																$ 0	$ 0	0	(1,950,503)	(1,950,503)
Warrants issued in bridge financing						$ 0	$ 0	$ 209,825	$ 0	$ 209,825
Balance (in shares) at Sep. 30, 2021																0	6,381,541
Balance at Sep. 30, 2021																$ 0	$ 6,382	$ 68,630,363	$ (50,632,895)	$ 18,003,850

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (4,827,314)	$ (1,621,546)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	26,806	2,983
Warrant issued for technology license fee	209,825	0
Gain on debt extinguishment	(172,056)	0
Changes in assets and liabilities:
Grant funds and other receivables	182,663	(72,551)
Prepaid expenses and other current assets	106,979	82,274
Amortization of debt discount	0	124,185
Accounts payable and accrued expenses	(289,477)	252,036
Total adjustments	314,043	412,927
Net cash used in operating activities	(4,513,271)	(1,208,619)
Cash flows from investing activities
Purchase of property and equipment	(47,718)	(2,470)
Net cash used in investing activities	(47,718)	(2,470)
Cash flows from financing activities:
Net proceeds from sale of common stock and warrants	9,408,920	11,158,496
Net proceeds from sale of preferred stock	0	300,000
Net proceeds from warrant exercises	3,404,156	0
Net proceeds from bridge financing	0	888,500
Net proceeds from issuance of note payable	0	170,200
Repurchase of preferred stock	(1,000)	0
Principal repayment of note payable	(27,864)	(8,854)
Net cash provided by financing activities	12,784,212	12,508,342
Net increase in cash and cash equivalents	8,223,223	11,297,253
Cash and cash equivalents at beginning of period	9,883,796	283,341
Cash and cash equivalents at end of period	18,107,019	11,580,594
Employees and Directors [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	168,570	0
Consultants [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	$ 80,733	$ 24,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($)	Sep. 29, 2020	Aug. 31, 2021	Feb. 28, 2021	Dec. 31, 2020
Common stock issued (in shares)				36,902
Common stock issued for cancellation of accrued compensation (in shares)	300,001
Deferred compensation	$ 1,500,000
Conversion from Convertible Debentures to Conversion Units [Member]
Shares issued upon conversion (in shares)	303,668
Convertible debentures	$ 1,200,000
Related accrued interest	$ 14,667
Stock Purchase Warrants First Issuance [Member]
Common stock issued (in shares)		3,839	145,866
Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]
Pre-funded stock purchase warrants (in shares)	126,042

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
ASSETS
Cash and cash equivalents	$ 18,107,019			$ 9,883,796				$ 283,341
Grant funds and other receivables	0			182,663				68,603
Prepaid expenses and other current assets	52,818			168,689				95,320
Total current assets	18,159,837			10,235,148				447,264
Property and equipment, net (Note 3)	168,653			147,741				10,606
Deposits	11,010			11,010				11,010
Total assets	18,339,500			10,393,899				468,880
Current liabilities:
Accounts payable	289,438			267,702				152,653
Accrued expenses (Note 4)	46,212			359,281				1,851,040
Current portion of notes payable	0			183,326				12,500
Total current liabilities	335,650			810,309				2,016,193
Note payable, net of current portion	0			14,738				27,243
Total liabilities	335,650			825,047				2,043,436
Commitments (Note 7)
Stockholders’ equity (deficiency):
Preferred stock, $.01 par value (Note 8): Authorized shares – 10,000,000 Issued and outstanding shares – 100 and 2,486 at December 31, 2020 and 2019, respectively	0			76,095				1,932,433
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 3,834,095 and 14,992 at December 31, 2020 and 2019, respectively	6,382			3,834				15
Additional paid-in capital	68,630,363			55,294,504				39,340,509
Accumulated deficit	(50,632,895)			(45,805,581)				(42,847,513)
Total stockholders’ equity (deficiency)	18,003,850	$ 19,458,338	$ 20,651,340	9,568,852	$ 10,813,744	$ (1,849,621)	$ (1,864,250)	(1,574,556)	$ (1,022,347)
Total liabilities and stockholders’ equity (deficiency)	$ 18,339,500			$ 10,393,899				$ 468,880

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)		10,000,000	10,000,000
Preferred stock, shares issued (in shares)		100	2,486
Preferred stock, shares outstanding (in shares)		100	2,486
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, authorized (in shares)	600,000,000	600,000,000	600,000,000
Common stock, issued (in shares)	6,381,541	3,834,095	14,992
Common stock, outstanding (in shares)	6,381,541	3,834,095	14,992

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Grant and collaboration revenue	$ 30,414			$ 415,458			$ 220,539	$ 1,572,037	$ 1,823,658	$ 1,175,896
Operating expenses:
Research and development	1,224,362			416,756			2,659,980	1,687,113	2,444,459	1,910,715
General and administrative	757,432			435,013			2,562,641	1,364,650	2,196,014	1,637,674
Total operating expenses	1,981,794			851,769			5,222,621	3,051,763	4,640,473	3,548,389
Loss from operations	(1,951,380)			(436,311)			(5,002,082)	(1,479,726)	(2,816,815)	(2,372,493)
Other income (expense):
Interest income	877			90			3,998	902	2,271	6,359
Interest expense	0			(134,427)			(1,286)	(142,722)	(143,524)	(4,495)
Total other income (expense)	877			(134,337)			174,768	(141,820)	(141,253)	1,864
Net loss	$ (1,950,503)	$ (1,314,033)	$ (1,562,778)	$ (570,648)	$ (455,204)	$ (595,694)	$ (4,827,314)	$ (1,621,546)	$ (2,958,068)	$ (2,370,629)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (0.31)			$ (0.73)			$ (0.80)	$ (2.85)	$ (2.14)	$ (781.87)
Weighted average shares outstanding (in shares)	6,349,297			782,978			6,005,032	569,955	1,383,829	3,032

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficiency) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018	3,450	11
Balance at Dec. 31, 2018	$ 1,971,333	$ 0	$ 37,483,204	$ (40,476,884)	$ (1,022,347)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	1,700	0
Sale of convertible preferred stock for cash and cancellation of note payable	$ 1,542,950	$ 0	147,050	0	1,690,000
Conversion of preferred stock to common stock (in shares)	(2,664)	14,819
Conversion of preferred stock to common stock	$ (1,581,850)	$ 15	1,581,835	0	$ 0
Issuance of common stock for services (in shares)	0	162			162
Issuance of common stock for services	$ 0	$ 0	24,000	0	$ 24,000
Stock option expense	0	0	104,420	0	104,420
Net loss	$ 0	$ 0	0	(2,370,629)	(2,370,629)
Balance (in shares) at Dec. 31, 2019	2,486	14,992
Balance at Dec. 31, 2019	$ 1,932,433	$ 15	39,340,509	(42,847,513)	(1,574,556)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	300
Sale of convertible preferred stock for cash and cancellation of note payable	$ 300,000				300,000
Conversion of preferred stock to common stock (in shares)	(2,386)	674,067
Conversion of preferred stock to common stock	$ (1,856,338)	$ 674	1,855,664
Issuance of common stock for services (in shares)	0	521
Issuance of common stock for services	$ 0	$ 1	5,999	0	6,000
Net loss				(595,694)	(595,694)
Balance (in shares) at Mar. 31, 2020	400	689,580
Balance at Mar. 31, 2020	$ 376,095	$ 690	41,202,172	(43,443,207)	(1,864,250)
Balance (in shares) at Dec. 31, 2019	2,486	14,992
Balance at Dec. 31, 2019	$ 1,932,433	$ 15	39,340,509	(42,847,513)	(1,574,556)
Net loss					(1,621,546)
Balance (in shares) at Sep. 30, 2020	100	3,559,473
Balance at Sep. 30, 2020	$ 76,095	$ 3,559	55,203,149	(44,469,059)	10,813,744
Balance (in shares) at Dec. 31, 2019	2,486	14,992
Balance at Dec. 31, 2019	$ 1,932,433	$ 15	39,340,509	(42,847,513)	(1,574,556)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	300	0
Sale of convertible preferred stock for cash and cancellation of note payable	$ 300,000	$ 0	0	0	300,000
Conversion of preferred stock to common stock (in shares)	(2,686)	716,790
Conversion of preferred stock to common stock	$ (2,156,338)	$ 717	2,155,621	0	$ 0
Issuance of common stock for services (in shares)	0	26,581			26,581
Issuance of common stock for services	$ 0	$ 27	94,373	0	$ 94,400
Stock option expense	0	0	18,730	0	18,730
Net loss	0	0	0	(2,958,068)	(2,958,068)
Warrants issued in bridge financing	$ 0	$ 0	457,833	0	$ 457,833
Common stock issued (in shares)	0	286,902			36,902
Issuance of common stock upon warrant exercise	$ 0	$ 287	2,213	0	$ 2,500
Issuance of common stock upon debenture conversion (in shares)	0	177,626
Issuance of common stock upon debenture conversion	$ 0	$ 177	569,340	0	569,517
Common stock issued for cancellation of accrued compensation (in shares)	0	300,001
Issuance of common stock upon cancellation of accrued compensation	$ 0	$ 300	1,499,700	0	1,500,000
Sale of common stock for cash (in shares)	0	2,310,000
Sale of common stock for cash	$ 0	$ 2,310	11,156,186	0	11,158,496
Roundup of shares following reverse stock split (in shares)	0	1,203
Roundup of shares following reverse stock split	$ 0	$ 1	(1)	0	0
Balance (in shares) at Dec. 31, 2020	100	3,834,095
Balance at Dec. 31, 2020	$ 76,095	$ 3,834	55,294,504	(45,805,581)	9,568,852
Balance (in shares) at Mar. 31, 2020	400	689,580
Balance at Mar. 31, 2020	$ 376,095	$ 690	41,202,172	(43,443,207)	(1,864,250)
Issuance of common stock for services (in shares)	0	2,124
Issuance of common stock for services	$ 0	$ 2	11,998	0	12,000
Net loss	$ 0	$ 0	0	(455,204)	(455,204)
Balance (in shares) at Jun. 30, 2020	400	691,704
Balance at Jun. 30, 2020	$ 376,095	$ 692	41,672,003	(43,898,411)	(1,849,621)
Conversion of preferred stock to common stock (in shares)	(300)	42,723
Conversion of preferred stock to common stock	$ (300,000)	$ 43	299,957	0	0
Issuance of common stock for services (in shares)	0	517
Issuance of common stock for services	$ 0	$ 0	6,000	0	6,000
Net loss	$ 0	$ 0	0	(570,648)	(570,648)
Common stock issued (in shares)	0	36,902
Common stock issued for cancellation of accrued compensation (in shares)	0	300,001
Issuance of common stock upon cancellation of accrued compensation	$ 0	$ 300	1,499,700	0	1,500,000
Sale of common stock for cash (in shares)	0	2,310,000
Sale of common stock for cash	$ 0	$ 2,310	11,156,186	0	11,158,496
Balance (in shares) at Sep. 30, 2020	100	3,559,473
Balance at Sep. 30, 2020	$ 76,095	$ 3,559	55,203,149	(44,469,059)	10,813,744
Balance (in shares) at Dec. 31, 2020	100	3,834,095
Balance at Dec. 31, 2020	$ 76,095	$ 3,834	55,294,504	(45,805,581)	9,568,852
Issuance of common stock for services (in shares)	0	1,472
Issuance of common stock for services	$ 0	$ 1	5,999	0	6,000
Stock option expense			56,190		56,190
Net loss				(1,562,778)	(1,562,778)
Common stock issued (in shares)	0	835,900
Issuance of common stock upon warrant exercise	$ 0	$ 836	3,173,320	0	3,174,156
Sale of common stock for cash (in shares)	0	1,644,000
Sale of common stock for cash	$ 0	$ 1,644	9,407,276	0	9,408,920
Balance (in shares) at Mar. 31, 2021	100	6,315,467
Balance at Mar. 31, 2021	$ 76,095	$ 6,315	67,937,289	(47,368,359)	20,651,340
Balance (in shares) at Dec. 31, 2020	100	3,834,095
Balance at Dec. 31, 2020	$ 76,095	$ 3,834	55,294,504	(45,805,581)	$ 9,568,852
Issuance of common stock for services (in shares)					13,707
Net loss					$ (4,827,314)
Balance (in shares) at Sep. 30, 2021	0	6,381,541
Balance at Sep. 30, 2021	$ 0	$ 6,382	68,630,363	(50,632,895)	18,003,850
Balance (in shares) at Mar. 31, 2021	100	6,315,467
Balance at Mar. 31, 2021	$ 76,095	$ 6,315	67,937,289	(47,368,359)	20,651,340
Issuance of common stock for services (in shares)	0	12,235
Issuance of common stock for services	$ 0	$ 13	65,828	0	65,841
Stock option expense	0	0	56,190	0	56,190
Net loss	$ 0	$ 0	0	(1,314,033)	(1,314,033)
Balance (in shares) at Jun. 30, 2021	0	6,327,702
Balance at Jun. 30, 2021	$ 0	$ 6,328	68,134,402	(48,682,392)	19,458,338
Stock option expense	0	0	56,190	0	56,190
Net loss	$ 0	$ 0	0	(1,950,503)	(1,950,503)
Common stock issued (in shares)	0	53,839
Issuance of common stock upon warrant exercise	$ 0	$ 54	229,946	0	230,000
Balance (in shares) at Sep. 30, 2021	0	6,381,541
Balance at Sep. 30, 2021	$ 0	$ 6,382	$ 68,630,363	$ (50,632,895)	$ 18,003,850

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (4,827,314)	$ (1,621,546)	$ (2,958,068)	$ (2,370,629)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	26,806	2,983	19,656	8,350
Amortization of debt discount	0	124,185	124,185	0
Stock-based compensation expense			64,463	327,500
Changes in assets and liabilities:
Grant funds and other receivables	182,663	(72,551)	(114,060)	53,211
Prepaid expenses and other current assets	106,979	82,274	(24,702)	(56,211)
Accounts payable and accrued expenses	(289,477)	252,036	137,956	639,282
Total adjustments	314,043	412,927	207,498	972,132
Net cash used in operating activities	(4,513,271)	(1,208,619)	(2,750,570)	(1,398,497)
Cash flows from investing activities
Purchase of property and equipment	(47,718)	(2,470)	(156,791)	(7,606)
Net cash used in investing activities	(47,718)	(2,470)	(156,791)	(7,606)
Cash flows from financing activities:
Net proceeds from sale of preferred stock	0	300,000	300,000	1,440,000
Net proceeds from issuance of note payable	0	170,200	170,200	0
Net proceeds from bridge financing	0	888,500	888,500	0
Net proceeds from sale of common stock and warrants	9,408,920	11,158,496	11,158,496	0
Net proceeds from warrant exercises	3,404,156	0	2,500	0
Principal repayment of note payable	(27,864)	(8,854)	(11,880)	(10,257)
Net cash provided by financing activities	12,784,212	12,508,342	12,507,816	1,429,743
Net increase in cash and cash equivalents	8,223,223	11,297,253	9,600,455	23,640
Cash and cash equivalents at beginning of period	9,883,796	283,341	283,341	259,701
Cash and cash equivalents at end of period	$ 18,107,019	$ 11,580,594	$ 9,883,796	$ 283,341

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parentheticals)	12 Months Ended
	Dec. 31, 2020shares
Common stock issued (in shares)	36,902

Note 1 - Description of Busines

Note 1 - Description of Business	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Nature of Operations [Text Block]	1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax’s Modified Vaccinia Ankara-Virus-Like Particle (MVA-VLP) based platform utilizes MVA, a large virus capable of carrying several vaccine antigens, to express proteins that assemble into highly effective virus-like particle (VLP) immunogens in the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector. GeoVax’s MVA-VLP development programs are focused primarily on preventive vaccines against the SARS-CoV- 2 19 On September 28, 2021, 1/2 no not GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.	1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using a novel vector vaccine platform (Modified Vaccinia Ankara (MVA) Virus-Like Particle, or “GV-MVA-VLP TM Our current development programs are focused on preventive vaccines against novel coronavirus (COVID- 19 Our corporate strategy is to advance, protect and exploit our differentiated vaccine immunotherapy platform leading to the successful development of preventive and therapeutic vaccines against infectious diseases and various cancers. With our design and development capabilities, we are progressing and validating an array of cancer and infectious disease immunotherapy and vaccine product candidates. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of Presentation The accompanying condensed consolidated financial statements at September 30, 2021 three nine September 30, 2021 2020 not 10 December 31, 2020. not We enacted reverse stock splits of our common stock on September 25, 2020 ( 1 January 21, 2020 ( 1 Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for at least the twelve may may no

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Significant Accounting Policies and Recent Accounting Pronouncements We disclosed in Note 2 10 December 31, 2020 nine September 30, 2021, no 10 no	2. Summary of Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation. Basis of Presentation Unless otherwise noted, the accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits described in Note 8. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We have funded our activities to date from government grants and clinical trial assistance, corporate and academic collaborations, and from sales of our equity securities. We believe that our existing cash resources together with current government funding commitments, will be sufficient to continue our planned operations into 2023. We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We may may no Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three Fair Value of Financial Instruments and Concentration of Credit Risk Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from three five We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016 02, Leases 2016 02 not 12 12 not Impairment of Long-Lived Assets We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not Accrued Expenses As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not third Net Loss Per Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 1,001,948 and 558 shares at December 31, 2020 2019, Revenue Recognition We recognize revenue in accordance with FASB Accounting Standards Update 2014 09, Revenue from Contracts with Customers 2014 09 606. five Grant revenue Research collaborations may third 2014 09 Research and Development Expense Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to third Patent Costs Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense. Period-to-Period Comparisons Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not Income Taxes We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not Stock-Based Compensation We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 8 Other Recent Accounting Pronouncements Except as discussed above, there have been no not

Note 4 - Basic and Diluted Loss

Note 4 - Basic and Diluted Loss Per Common Share	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share totaled 2,965,451 and 2,550,184 shares for the three nine September 30, 2021, three nine September 30, 2020,

Note 5 - Property and Equipment

Note 5 - Property and Equipment	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of September 30, 2021 December 31, 2020: September 30, 2021 December 31, 2020 Equipment and furnishings $ 591,554 $ 543,836 Leasehold improvements 115,605 115,605 Total property and equipment 707,159 659,441 Accumulated depreciation and amortization (538,506 ) (511,700 ) Property and equipment, net $ 168,653 $ 147,741	3. Property and Equipment Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2020 2019: 2020 2019 Laboratory equipment $ 532,100 $ 534,577 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total property and equipment 659,441 661,918 Accumulated depreciation and amortization (511,700 ) (651,312 ) Property and equipment, net $ 147,741 $ 10,606 Depreciation expense was $19,656 and $8,350 during the years ended December 31, 2020 2019,

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued Expenses Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets are composed of the following as of September 30, 2021 December 31, 2020: September 30, 2021 December 31, 2020 Accrued salaries $ 11,212 $ 279,696 Other accrued expenses 35,000 79,585 Total accrued expenses $ 46,212 $ 359,281	4. Accrued Expenses Accrued expenses as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2020 2019: 2020 2019 Accrued salaries and directors’ fees $ 279,696 $ 1,732,702 Other accrued expenses 79,585 118,338 Total accrued expenses $ 359,281 $ 1,851,040

Note 7 - Notes Payable

Note 7 - Notes Payable	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Notes Payable GRA Note February 28, 2018, five five three nine September 30, 2021 2020. May 2021, CARES Act Paycheck Protection Program Loan April 17, 2020, one three nine September 30, 2021, 2020. May 2021,	5. Notes Payable GRA Note February 28, 2018, five second 2021, in2022, 2023. December 31, 2020 2019, CARES Act Paycheck Protection Program Loan April 17, 2020, one April 17, 2022. October 2020, not

Note 8 - Commitments

Note 8 - Commitments	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Commitments Disclosure [Text Block]	8. Commitments Lease Agreement We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on December 31, 2022. three nine September 30, 2021 2020. 2021 2022, may ninety Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of September 30, 2021, 2021.	7. Commitments Lease Agreement We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on December 31, 2022. December 31, 2020 2019 2021 2022, may ninety Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of December 31, 2020, 2021.

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Preferred Stock [Text Block]	9. Stockholders Equity Preferred Stock June 7, 2021, September 30, 2021, Public Offering February 11, 2021, Stock Options “2020 may 2020 nine September 30, 2021, no 2020 September 30, 2021, Stock Purchase Warrants January February 2021, During August 2021, On September 28, 2021, five As of September 30, 2021, Other Common Stock Transactions nine September 30, 2021,	8. Stockholders Equity Convertible Preferred Stock We are authorized to issue up to 10,000,000 shares of our Preferred Stock, $.01 may one December 31, 2020 2019. December 31, 2020 2019 December 31, 2020 December 31, 2019 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series H Convertible Preferred Stock - - 1,686 1,156,338 Series I Convertible Preferred Stock - - 700 700,000 Total 100 $ 76,095 2,486 $ 1,932,433 Series B Convertible Preferred Stock no not December 31, 2020, Series C Convertible Preferred Stock no not 2019, December 31, 2020, Series E Convertible Preferred Stock no not 2019, December 31, 2020, Series F Preferred Stock February 2019, no not 2019, December 31, 2020, Series G Preferred Stock February 2019, three no not first February 2019, $250,000. second third April June 2019, July 2019, December 31, 2020, Series H Preferred Stock July 2019, no not 2019, 2020, December 31, 2020, Series I Preferred Stock July 2019, no not 2020, December 31, 2020, Series J Preferred Stock January 2020, no not 2020, December 31, 2020, Common Stock Reverse Stock Splits April 30, 2019, 1 January 21, 2020, 1 September 25, 2020, 1 Conversions of Preferred Stock 2020 2019 Public Offering September 24, 2020, September 29, 2020, Of the 2,560,000 Units sold in the Offering: (a) 2,310,000 Units consist of one one one one October 2020. one five Pursuant to the Underwriting Agreement, we issued to the Representative, as a portion of the underwriting compensation, warrants to purchase up to a total of 128,000 shares of common stock (the “Representative Warrants”). The Representative Warrants have an exercise price of $5.50 per share, are initially exercisable 180 days after the effective date of the Offering and have a term of three Conversion of Deferred Compensation to Equity 2016 August 2020, September 29, 2020, one one Conversion of Convertible Debentures to Equity 6, Other Common Stock Transactions 2020 2019 2020, Stock Options We have a stock-based incentive plan (the “2020 may 2020 may not ten three We use the Black-Scholes model for determining the grant date fair value of our stock option grants. This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted. The significant assumptions we used in our fair value calculations were as follows: 2020 2019 Weighted average risk-free interest rates 0.69 % N/A Expected dividend yield 0.0 % N/A Expected life of option (years) 7.0 N/A Expected volatility 38.16 % N/A A summary of stock option activity under the 2020 December 31, 2020, Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (yrs) Aggregate Intrinsic Value Outstanding at December 31, 2019 - $ - Granted 602,000 2.79 Exercised - - Forfeited or expired - - Outstanding at December 31, 2020 602,000 $ 2.79 9.9 $ 355,180 Exercisable at December 31, 2020 -0- $ - - $ - The weighted-average grant date fair value of options granted during 2020 No 2019. December 31, 2020 2019 December 31, 2020, Stock Purchase Warrants Summary of Warrants Outstanding December 31, 2020. Warrant Description Number of Shares Exercise Price Expiration Series I Warrants 62,626 $ 5.00 Oct-Dec 2024 June 2020 Warrants 120,000 5.00 Jun 2025 Pre-Funded Warrants 126,042 0.01 Perpetual Unit, Conversion and Management Warrants 3,163,669 5.00 Sep 2025 Representative Warrants 128,000 5.50 Mar 2024 Total Warrants Outstanding at December 31, 2020 3,600,337 Weighted-Average Exercise Price $ 4.84 Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years) 4.7 Series I Warrants July 2020, December 31, 2020, June 2020 6, June 26, 2020, five September 29, 2020 Warrants Issued Upon Conversion of Convertible Debentures 6, September 29, 2020, Warrants Issued Upon Conversion of Deferred Compensation Common Stock Conversion of Deferred Compensation to Equity September 29, 2020, Warrants Issued in Connection with Public Offering Common Stock Public Offering September 29, 2020, October 2020), Additional Stock-Based Compensation Expense In addition to stock-based compensation expense related to the 2020 Stock Options December 31, 2020 2019, December 31, 2020, one 2021

Note 10 - Stock-based Expense

Note 10 - Stock-based Expense	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	10. Stock-Based Expense Stock-based compensation expense related to employee and director stock options was $56,190 and $168,570 during the three nine September 30, 2021, 2020. September 30, 2021, During the three nine September 30, 2021, 2020. September 30, 2021, During September 2021,

Note 11 - Income Taxes

Note 11 - Income Taxes	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11. Income Taxes Because of our historically significant net operating losses, we have not 382 may	10. Income Taxes At December 31, 2020, 2021 2037. 2022 2040 382 may may Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at December 31, 2020 2019: 2020 2019 Deferred tax assets: Net operating loss carryforward $ 14,737,240 $ 15,328,336 Research and development tax credit carryforward 1,189,110 1,122,536 Stock-based compensation expense 4,870 1,877,284 Accrued salaries and directors’ fees 72,721 450,503 Depreciation - 8,571 Total deferred tax assets 16,003,941 18,787,230 Deferred tax liabilities Depreciation 28,274 - Net deferred tax assets 15,975,667 18,787,230 Valuation allowance (15,975,667 ) (18,787,230 ) Net deferred tax asset after reduction for valuation allowance $ -0- $ -0- We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows: 2020 2019 U.S. federal statutory rate applied to pretax loss $ (621,194 ) $ (497,833 ) Permanent differences 65 278 Research and development credits (66,574 ) (47,053 ) Change in valuation allowance, net of expired items and other adjustments 687,703 544,308 Reported income tax expense $ -0- $ -0-

Note 12 - Grants and Collaborat

Note 12 - Grants and Collaboration Revenue	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Government Grants and Contracts [Text Block]	12. Grants and Collaboration Revenue We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three nine September 30, 2021, 2020. three nine September 30, 2020, third September 30, 2021, 2022.	11. Grants and Collaboration Revenue We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During 2020 2019, December 31, 2020, 2021. 2020 2019, third

Note 13 - Subsequent Event

Note 13 - Subsequent Event	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	13. Subsequent Event On November 9, 2021, 19 30 first second	12. Subsequent Events SBIR Grant January 2021, 2, 19. 1 Preclinical Development of GV-MVA-VLP Vaccines Against COVID- 19, Warrant Exercises January February 2021, Bought Deal Public Offering -- February 11, 2021,

Note 1 - Description of Busin_2

Note 1 - Description of Business	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Nature of Operations [Text Block]	1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax’s Modified Vaccinia Ankara-Virus-Like Particle (MVA-VLP) based platform utilizes MVA, a large virus capable of carrying several vaccine antigens, to express proteins that assemble into highly effective virus-like particle (VLP) immunogens in the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector. GeoVax’s MVA-VLP development programs are focused primarily on preventive vaccines against the SARS-CoV- 2 19 On September 28, 2021, 1/2 no not GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.	1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using a novel vector vaccine platform (Modified Vaccinia Ankara (MVA) Virus-Like Particle, or “GV-MVA-VLP TM Our current development programs are focused on preventive vaccines against novel coronavirus (COVID- 19 Our corporate strategy is to advance, protect and exploit our differentiated vaccine immunotherapy platform leading to the successful development of preventive and therapeutic vaccines against infectious diseases and various cancers. With our design and development capabilities, we are progressing and validating an array of cancer and infectious disease immunotherapy and vaccine product candidates. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Significant Accounting Policies and Recent Accounting Pronouncements We disclosed in Note 2 10 December 31, 2020 nine September 30, 2021, no 10 no	2. Summary of Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation. Basis of Presentation Unless otherwise noted, the accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits described in Note 8. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We have funded our activities to date from government grants and clinical trial assistance, corporate and academic collaborations, and from sales of our equity securities. We believe that our existing cash resources together with current government funding commitments, will be sufficient to continue our planned operations into 2023. We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We may may no Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three Fair Value of Financial Instruments and Concentration of Credit Risk Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from three five We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016 02, Leases 2016 02 not 12 12 not Impairment of Long-Lived Assets We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not Accrued Expenses As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not third Net Loss Per Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 1,001,948 and 558 shares at December 31, 2020 2019, Revenue Recognition We recognize revenue in accordance with FASB Accounting Standards Update 2014 09, Revenue from Contracts with Customers 2014 09 606. five Grant revenue Research collaborations may third 2014 09 Research and Development Expense Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to third Patent Costs Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense. Period-to-Period Comparisons Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not Income Taxes We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not Stock-Based Compensation We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 8 Other Recent Accounting Pronouncements Except as discussed above, there have been no not

Note 3 - Property and Equipment

Note 3 - Property and Equipment	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of September 30, 2021 December 31, 2020: September 30, 2021 December 31, 2020 Equipment and furnishings $ 591,554 $ 543,836 Leasehold improvements 115,605 115,605 Total property and equipment 707,159 659,441 Accumulated depreciation and amortization (538,506 ) (511,700 ) Property and equipment, net $ 168,653 $ 147,741	3. Property and Equipment Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2020 2019: 2020 2019 Laboratory equipment $ 532,100 $ 534,577 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total property and equipment 659,441 661,918 Accumulated depreciation and amortization (511,700 ) (651,312 ) Property and equipment, net $ 147,741 $ 10,606 Depreciation expense was $19,656 and $8,350 during the years ended December 31, 2020 2019,

Note 4 - Accrued Expenses

Note 4 - Accrued Expenses	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued Expenses Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets are composed of the following as of September 30, 2021 December 31, 2020: September 30, 2021 December 31, 2020 Accrued salaries $ 11,212 $ 279,696 Other accrued expenses 35,000 79,585 Total accrued expenses $ 46,212 $ 359,281	4. Accrued Expenses Accrued expenses as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2020 2019: 2020 2019 Accrued salaries and directors’ fees $ 279,696 $ 1,732,702 Other accrued expenses 79,585 118,338 Total accrued expenses $ 359,281 $ 1,851,040

Note 5 - Notes Payable

Note 5 - Notes Payable	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Notes Payable GRA Note February 28, 2018, five five three nine September 30, 2021 2020. May 2021, CARES Act Paycheck Protection Program Loan April 17, 2020, one three nine September 30, 2021, 2020. May 2021,	5. Notes Payable GRA Note February 28, 2018, five second 2021, in2022, 2023. December 31, 2020 2019, CARES Act Paycheck Protection Program Loan April 17, 2020, one April 17, 2022. October 2020, not

Note 6 - Convertible Debentures

Note 6 - Convertible Debentures	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Short-term Debt [Text Block]	6. Convertible Debentures On June 26 2020, two $1,200,000; five “June 2020 8, September 29, 2020 June 2020 twelve The Convertible Debentures were mandatorily convertible upon our consummation of a public offering of common stock with gross proceeds of $6,000,000 or more, and which resulted in the listing of our common stock on a national securities exchange (a “Qualified Offering”). The conversion price upon the occurrence of a Qualified Offering was equal to the lower of (i) $10.00 per share or (ii) 80% of the offering price. The conversion provisions of the Convertible Debentures were subject to a “conversion blocker” such that each of the purchasers could not On September 29, 2020, 8, 303,668 one one one one one not one five Upon the issuance of the Convertible Debentures, we recorded a debt discount of $769,334, including the $150,000 original issue discount, $457,833 of fair value allocated to the warrants (recorded as Additional Paid-in Capital), and $161,500 of direct transaction costs incurred. The debt discount was amortized to interest expense over the 12 September 29, 2020, 2020

Note 7 - Commitments

Note 7 - Commitments	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Commitments Disclosure [Text Block]	8. Commitments Lease Agreement We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on December 31, 2022. three nine September 30, 2021 2020. 2021 2022, may ninety Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of September 30, 2021, 2021.	7. Commitments Lease Agreement We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on December 31, 2022. December 31, 2020 2019 2021 2022, may ninety Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of December 31, 2020, 2021.

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Preferred Stock [Text Block]	9. Stockholders Equity Preferred Stock June 7, 2021, September 30, 2021, Public Offering February 11, 2021, Stock Options “2020 may 2020 nine September 30, 2021, no 2020 September 30, 2021, Stock Purchase Warrants January February 2021, During August 2021, On September 28, 2021, five As of September 30, 2021, Other Common Stock Transactions nine September 30, 2021,	8. Stockholders Equity Convertible Preferred Stock We are authorized to issue up to 10,000,000 shares of our Preferred Stock, $.01 may one December 31, 2020 2019. December 31, 2020 2019 December 31, 2020 December 31, 2019 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series H Convertible Preferred Stock - - 1,686 1,156,338 Series I Convertible Preferred Stock - - 700 700,000 Total 100 $ 76,095 2,486 $ 1,932,433 Series B Convertible Preferred Stock no not December 31, 2020, Series C Convertible Preferred Stock no not 2019, December 31, 2020, Series E Convertible Preferred Stock no not 2019, December 31, 2020, Series F Preferred Stock February 2019, no not 2019, December 31, 2020, Series G Preferred Stock February 2019, three no not first February 2019, $250,000. second third April June 2019, July 2019, December 31, 2020, Series H Preferred Stock July 2019, no not 2019, 2020, December 31, 2020, Series I Preferred Stock July 2019, no not 2020, December 31, 2020, Series J Preferred Stock January 2020, no not 2020, December 31, 2020, Common Stock Reverse Stock Splits April 30, 2019, 1 January 21, 2020, 1 September 25, 2020, 1 Conversions of Preferred Stock 2020 2019 Public Offering September 24, 2020, September 29, 2020, Of the 2,560,000 Units sold in the Offering: (a) 2,310,000 Units consist of one one one one October 2020. one five Pursuant to the Underwriting Agreement, we issued to the Representative, as a portion of the underwriting compensation, warrants to purchase up to a total of 128,000 shares of common stock (the “Representative Warrants”). The Representative Warrants have an exercise price of $5.50 per share, are initially exercisable 180 days after the effective date of the Offering and have a term of three Conversion of Deferred Compensation to Equity 2016 August 2020, September 29, 2020, one one Conversion of Convertible Debentures to Equity 6, Other Common Stock Transactions 2020 2019 2020, Stock Options We have a stock-based incentive plan (the “2020 may 2020 may not ten three We use the Black-Scholes model for determining the grant date fair value of our stock option grants. This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted. The significant assumptions we used in our fair value calculations were as follows: 2020 2019 Weighted average risk-free interest rates 0.69 % N/A Expected dividend yield 0.0 % N/A Expected life of option (years) 7.0 N/A Expected volatility 38.16 % N/A A summary of stock option activity under the 2020 December 31, 2020, Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (yrs) Aggregate Intrinsic Value Outstanding at December 31, 2019 - $ - Granted 602,000 2.79 Exercised - - Forfeited or expired - - Outstanding at December 31, 2020 602,000 $ 2.79 9.9 $ 355,180 Exercisable at December 31, 2020 -0- $ - - $ - The weighted-average grant date fair value of options granted during 2020 No 2019. December 31, 2020 2019 December 31, 2020, Stock Purchase Warrants Summary of Warrants Outstanding December 31, 2020. Warrant Description Number of Shares Exercise Price Expiration Series I Warrants 62,626 $ 5.00 Oct-Dec 2024 June 2020 Warrants 120,000 5.00 Jun 2025 Pre-Funded Warrants 126,042 0.01 Perpetual Unit, Conversion and Management Warrants 3,163,669 5.00 Sep 2025 Representative Warrants 128,000 5.50 Mar 2024 Total Warrants Outstanding at December 31, 2020 3,600,337 Weighted-Average Exercise Price $ 4.84 Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years) 4.7 Series I Warrants July 2020, December 31, 2020, June 2020 6, June 26, 2020, five September 29, 2020 Warrants Issued Upon Conversion of Convertible Debentures 6, September 29, 2020, Warrants Issued Upon Conversion of Deferred Compensation Common Stock Conversion of Deferred Compensation to Equity September 29, 2020, Warrants Issued in Connection with Public Offering Common Stock Public Offering September 29, 2020, October 2020), Additional Stock-Based Compensation Expense In addition to stock-based compensation expense related to the 2020 Stock Options December 31, 2020 2019, December 31, 2020, one 2021

Note 9 - Retirement Plan

Note 9 - Retirement Plan	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Retirement Benefits [Text Block]	9. Retirement Plan We participate in a multi-employer defined contribution retirement plan (the “401k third 401k December 31, 2020 2019 401k

Note 10 - Income Taxes

Note 10 - Income Taxes	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11. Income Taxes Because of our historically significant net operating losses, we have not 382 may	10. Income Taxes At December 31, 2020, 2021 2037. 2022 2040 382 may may Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at December 31, 2020 2019: 2020 2019 Deferred tax assets: Net operating loss carryforward $ 14,737,240 $ 15,328,336 Research and development tax credit carryforward 1,189,110 1,122,536 Stock-based compensation expense 4,870 1,877,284 Accrued salaries and directors’ fees 72,721 450,503 Depreciation - 8,571 Total deferred tax assets 16,003,941 18,787,230 Deferred tax liabilities Depreciation 28,274 - Net deferred tax assets 15,975,667 18,787,230 Valuation allowance (15,975,667 ) (18,787,230 ) Net deferred tax asset after reduction for valuation allowance $ -0- $ -0- We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows: 2020 2019 U.S. federal statutory rate applied to pretax loss $ (621,194 ) $ (497,833 ) Permanent differences 65 278 Research and development credits (66,574 ) (47,053 ) Change in valuation allowance, net of expired items and other adjustments 687,703 544,308 Reported income tax expense $ -0- $ -0-

Note 11 - Grants and Collaborat

Note 11 - Grants and Collaboration Revenue	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Government Grants and Contracts [Text Block]	12. Grants and Collaboration Revenue We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three nine September 30, 2021, 2020. three nine September 30, 2020, third September 30, 2021, 2022.	11. Grants and Collaboration Revenue We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During 2020 2019, December 31, 2020, 2021. 2020 2019, third

Note 12 - Subsequent Events

Note 12 - Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	13. Subsequent Event On November 9, 2021, 19 30 first second	12. Subsequent Events SBIR Grant January 2021, 2, 19. 1 Preclinical Development of GV-MVA-VLP Vaccines Against COVID- 19, Warrant Exercises January February 2021, Bought Deal Public Offering -- February 11, 2021,

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	GEOVAX LABS, INC. SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS For the Years Ended December 31, 2020 2019 Additions (Reductions) Description Balance at Beginning Of Period Charged to Costs and Expenses Charged to Other Accounts Deductions Balance at End Of Period Reserve Deducted in the Balance Sheet From the Asset to Which it Applies: Allowance for Deferred Tax Assets Year ended December 31, 2020 $ 18,787,230 $ (2,811,563 ) $ -0- $ -0- $ 15,975,667 Year ended December 31, 2019 19,879,954 (1,092,724 ) -0- -0- 18,787,230

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation Unless otherwise noted, the accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits described in Note 8. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We have funded our activities to date from government grants and clinical trial assistance, corporate and academic collaborations, and from sales of our equity securities. We believe that our existing cash resources together with current government funding commitments, will be sufficient to continue our planned operations into 2023. We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We may may no
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments and Concentration of Credit Risk Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from three five We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016 02, Leases 2016 02 not 12 12 not
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not
Accrued Liabilities [Policy Text Block]	Accrued Expenses As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not third
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 1,001,948 and 558 shares at December 31, 2020 2019,
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition We recognize revenue in accordance with FASB Accounting Standards Update 2014 09, Revenue from Contracts with Customers 2014 09 606. five Grant revenue Research collaborations may third 2014 09
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to third
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patent Costs Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.
Reclassification, Comparability Adjustment [Policy Text Block]	Period-to-Period Comparisons Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not
Income Tax, Policy [Policy Text Block]	Income Taxes We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 8
New Accounting Pronouncements, Policy [Policy Text Block]	Other Recent Accounting Pronouncements Except as discussed above, there have been no not

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, 2021 December 31, 2020 Equipment and furnishings $ 591,554 $ 543,836 Leasehold improvements 115,605 115,605 Total property and equipment 707,159 659,441 Accumulated depreciation and amortization (538,506 ) (511,700 ) Property and equipment, net $ 168,653 $ 147,741	2020 2019 Laboratory equipment $ 532,100 $ 534,577 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total property and equipment 659,441 661,918 Accumulated depreciation and amortization (511,700 ) (651,312 ) Property and equipment, net $ 147,741 $ 10,606

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, 2021 December 31, 2020 Accrued salaries $ 11,212 $ 279,696 Other accrued expenses 35,000 79,585 Total accrued expenses $ 46,212 $ 359,281	2020 2019 Accrued salaries and directors’ fees $ 279,696 $ 1,732,702 Other accrued expenses 79,585 118,338 Total accrued expenses $ 359,281 $ 1,851,040

Note 3 - Property and Equipme_2

Note 3 - Property and Equipment (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, 2021 December 31, 2020 Equipment and furnishings $ 591,554 $ 543,836 Leasehold improvements 115,605 115,605 Total property and equipment 707,159 659,441 Accumulated depreciation and amortization (538,506 ) (511,700 ) Property and equipment, net $ 168,653 $ 147,741	2020 2019 Laboratory equipment $ 532,100 $ 534,577 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total property and equipment 659,441 661,918 Accumulated depreciation and amortization (511,700 ) (651,312 ) Property and equipment, net $ 147,741 $ 10,606

Note 4 - Accrued Expenses (Tabl

Note 4 - Accrued Expenses (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, 2021 December 31, 2020 Accrued salaries $ 11,212 $ 279,696 Other accrued expenses 35,000 79,585 Total accrued expenses $ 46,212 $ 359,281	2020 2019 Accrued salaries and directors’ fees $ 279,696 $ 1,732,702 Other accrued expenses 79,585 118,338 Total accrued expenses $ 359,281 $ 1,851,040

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Preferred Stock [Table Text Block]	December 31, 2020 December 31, 2019 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series H Convertible Preferred Stock - - 1,686 1,156,338 Series I Convertible Preferred Stock - - 700 700,000 Total 100 $ 76,095 2,486 $ 1,932,433
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2020 2019 Weighted average risk-free interest rates 0.69 % N/A Expected dividend yield 0.0 % N/A Expected life of option (years) 7.0 N/A Expected volatility 38.16 % N/A
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (yrs) Aggregate Intrinsic Value Outstanding at December 31, 2019 - $ - Granted 602,000 2.79 Exercised - - Forfeited or expired - - Outstanding at December 31, 2020 602,000 $ 2.79 9.9 $ 355,180 Exercisable at December 31, 2020 -0- $ - - $ -
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant Description Number of Shares Exercise Price Expiration Series I Warrants 62,626 $ 5.00 Oct-Dec 2024 June 2020 Warrants 120,000 5.00 Jun 2025 Pre-Funded Warrants 126,042 0.01 Perpetual Unit, Conversion and Management Warrants 3,163,669 5.00 Sep 2025 Representative Warrants 128,000 5.50 Mar 2024 Total Warrants Outstanding at December 31, 2020 3,600,337 Weighted-Average Exercise Price $ 4.84 Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years) 4.7

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2020 2019 Deferred tax assets: Net operating loss carryforward $ 14,737,240 $ 15,328,336 Research and development tax credit carryforward 1,189,110 1,122,536 Stock-based compensation expense 4,870 1,877,284 Accrued salaries and directors’ fees 72,721 450,503 Depreciation - 8,571 Total deferred tax assets 16,003,941 18,787,230 Deferred tax liabilities Depreciation 28,274 - Net deferred tax assets 15,975,667 18,787,230 Valuation allowance (15,975,667 ) (18,787,230 ) Net deferred tax asset after reduction for valuation allowance $ -0- $ -0-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2020 2019 U.S. federal statutory rate applied to pretax loss $ (621,194 ) $ (497,833 ) Permanent differences 65 278 Research and development credits (66,574 ) (47,053 ) Change in valuation allowance, net of expired items and other adjustments 687,703 544,308 Reported income tax expense $ -0- $ -0-

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Summary of Valuation Allowance [Table Text Block]	Additions (Reductions) Description Balance at Beginning Of Period Charged to Costs and Expenses Charged to Other Accounts Deductions Balance at End Of Period Reserve Deducted in the Balance Sheet From the Asset to Which it Applies: Allowance for Deferred Tax Assets Year ended December 31, 2020 $ 18,787,230 $ (2,811,563 ) $ -0- $ -0- $ 15,975,667 Year ended December 31, 2019 19,879,954 (1,092,724 ) -0- -0- 18,787,230

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation (Details Textual)	Sep. 25, 2020	Jan. 21, 2020	Apr. 30, 2019
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20	2,000	500

Note 4 - Basic and Diluted Lo_2

Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	2,965,451	204,553	2,550,184	78,754	1,001,948	558

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Property and equipment, gross	$ 707,159	$ 659,441	$ 661,918
Accumulated depreciation and amortization	(538,506)	(511,700)	(651,312)
Property and equipment, net	168,653	147,741	10,606
Equipment and Furnishings [Member]
Property and equipment, gross	591,554	543,836
Leasehold Improvements [Member]
Property and equipment, gross	$ 115,605	$ 115,605	$ 115,605

Note 6 - Accrued Expenses - Sch

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Accrued salaries	$ 11,212	$ 279,696	$ 1,732,702
Other accrued expenses	35,000	79,585	118,338
Total accrued expenses	$ 46,212	$ 359,281	$ 1,851,040

Note 7 - Notes Payable (Details

Note 7 - Notes Payable (Details Textual) - USD ($)	Apr. 17, 2020	Feb. 28, 2018	May 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Proceeds from Notes Payable, Total						$ 0	$ 170,200	$ 170,200	$ 0
Repayments of Notes Payable						27,864	8,854	11,880	$ 10,257
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total	$ 170,200
Interest Expense, Debt, Total				$ 0	$ 429	653	774	$ 1,203
Extinguishment of Debt, Amount			$ 170,200
Gain (Loss) from Interest Forgiven			1,856
Senior Notes [Member]
Debt Instrument, Term (Year)		5 years
Proceeds from Notes Payable, Total		$ 50,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Interest Expense, Debt, Total				$ 0	$ 411	$ 633	$ 1,344
Repayments of Notes Payable			$ 22,737

Note 8 - Commitments (Details T

Note 8 - Commitments (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)ft²	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)ft²	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)ft²
Area of Real Estate Property (Square Foot) | ft²					8,400
Lessee, Operating Lease, Liability, to be Paid, Year One					$ 171,213
Unrecorded Unconditional Purchase Obligation, Total	$ 607,000		$ 607,000		$ 190,000
Office and Laboratory Lease Agreement [Member]
Area of Real Estate Property (Square Foot) | ft²	8,400		8,400
Operating Lease, Expense	$ 42,803	$ 41,539	$ 128,410	$ 124,617
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year	42,803		42,803
Lessee, Operating Lease, Liability, to be Paid, Year One	$ 176,356		$ 176,356

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Details Textual) - USD ($)	Jun. 07, 2021	Feb. 11, 2021	Aug. 31, 2021	Feb. 28, 2021	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Sep. 28, 2021	Sep. 29, 2020	Sep. 24, 2020
Stock Repurchased During Period, Value					$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								100	2,486
Stock Issued During Period, Shares, New Issues (in shares)		1,644,000
Shares Issued, Price Per Share (in dollars per share)		$ 6.25
Proceeds from Issuance of Common Stock		$ 9,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						0		602,000	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)						602,000		602,000	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)						$ 2.79		$ 2.79	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)						9 years 2 months 12 days		9 years 10 months 24 days
Stock Issued During Period, Shares, Warrants Exercised (in shares)								36,902
Proceeds from Warrant Exercises			$ 230,000	$ 3,174,156		$ 3,404,156	$ 0	$ 2,500	$ 0
Class of Warrant or Right, Outstanding (in shares)								3,600,337
Stock Issued During Period, Shares, Issued for Services (in shares)						13,707		26,581	162
Stock Incentive Plan 2020 [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)						1,500,000		1,000,000
Representative Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		72,000									128,000	128,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.875						$ 5.50				$ 5.50
Warrants and Rights Outstanding, Term (Year)												3 years
Class of Warrant or Right, Outstanding (in shares)								128,000
Stock Purchase Warrants First Issuance [Member]
Class of Warrant or Right, Exercised During Period (in shares)			27,004	188,688
Stock Issued During Period, Shares, Warrants Exercised (in shares)			3,839	145,866
Stock Purchase Warrants Second Issuance [Member]
Class of Warrant or Right, Exercised During Period (in shares)			50,000	690,034
Stock Issued During Period, Shares, Warrants Exercised (in shares)			50,000	690,034
Stock Purchase Warrant to PNP [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)										100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 13
Warrants and Rights Outstanding, Term (Year)										5 years
Stock Purchase Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 5.35
Warrants and Rights Outstanding, Term (Year)						3 years 10 months 24 days
Class of Warrant or Right, Outstanding (in shares)						2,816,631
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)		204,000
Series B Convertible Preferred Stock [Member]
Stock Repurchased During Period, Shares (in shares)	100
Stock Repurchased During Period, Value	$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)						0		100	100

Note 10 - Stock-based Expense (

Note 10 - Stock-based Expense (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 486,940	$ 486,940		$ 486,940
Stock Issued During Period, Value Expensed During the Period, Issued for Services		29,560	$ 6,000	80,733	$ 24,000
Prepaid Expense, Value of Stock Issued for Services During Period	39,773	39,773		39,773		$ 48,667
Research and Development Expense [Member]
Warrant Issuance Expense	$ 209,825
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense		$ 56,190	$ 0	$ 168,570	$ 0	$ 18,730	$ 104,420
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				2 years 2 months 12 days		2 years 10 months 24 days

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Income Taxes Paid	$ 0	$ 0

Note 12 - Grants and Collabor_2

Note 12 - Grants and Collaboration Revenue (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Revenue from Contract with Customer, Including Assessed Tax	$ 30,414	$ 415,458	$ 220,539	$ 1,572,037	$ 1,823,658	$ 1,175,896
Unused Grant Funds	244,888		244,888		165,500
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 30,414	231,330	$ 220,539	1,186,844	$ 1,438,465	$ 983,682
Leidos, Inc. Research Collaborative Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 184,128		$ 385,193

Note 13 - Subsequent Event (Det

Note 13 - Subsequent Event (Details Textual) - City of Hope [Member] - Subsequent Event [Member]	Nov. 09, 2021USD ($)
Upfront Fee	$ 5,000,000
License First Anniversary Payment [Member]
License Fees	3,000,000
License Second Anniversary Payment [Member]
License Fees	$ 2,000,000

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual) - shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	2,965,451	204,553	2,550,184	78,754	1,001,948	558
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)					3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)					5 years

Note 3 - Property and Equipme_3

Note 3 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Depreciation, Depletion and Amortization, Nonproduction, Total	$ 19,656	$ 8,350

Note 3 - Property and Equipme_4

Note 3 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Property and equipment, gross	$ 707,159	$ 659,441	$ 661,918
Accumulated depreciation and amortization	(538,506)	(511,700)	(651,312)
Property and equipment, net	168,653	147,741	10,606
Laboratory Equipment [Member]
Property and equipment, gross		532,100	534,577
Leasehold Improvements [Member]
Property and equipment, gross	$ 115,605	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross		$ 11,736	$ 11,736

Note 4 - Accrued Expenses - Sch

Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Accrued salaries	$ 11,212	$ 279,696	$ 1,732,702
Other accrued expenses	35,000	79,585	118,338
Total accrued expenses	$ 46,212	$ 359,281	$ 1,851,040

Note 5 - Notes Payable (Details

Note 5 - Notes Payable (Details Textual) - USD ($)	Apr. 17, 2020	Feb. 28, 2018	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Proceeds from Notes Payable, Total					$ 0	$ 170,200	$ 170,200	$ 0
Interest Expense, Total			$ 0	$ 134,427	1,286	142,722	143,524	4,495
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total	$ 170,200
Interest Expense, Debt, Total			0	429	653	774	1,203
Senior Notes [Member]
Debt Instrument, Term (Year)		5 years
Proceeds from Notes Payable, Total		$ 50,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Long-Term Debt, Maturity, Year One							12,487
Long-Term Debt, Maturity, Year Two							13,126
Long-Term Debt, Maturity, Year Three							2,252
Interest Expense, Total							$ 1,727	$ 2,097
Interest Expense, Debt, Total			$ 0	$ 411	$ 633	$ 1,344

Note 6 - Convertible Debentur_2

Note 6 - Convertible Debentures (Details Textual)	Sep. 29, 2020USD ($)$ / sharesshares	Jun. 26, 2020USD ($)$ / sharesshares	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)	Sep. 24, 2020$ / sharesshares
Proceeds from Convertible Debt			$ 0	$ 888,500	$ 888,500	$ 0
Number of Common Stock Securities Called by Each Unit (in shares) | shares	1
Amortization of Debt Discount (Premium)			$ 0	$ 124,185	$ 124,185	$ 0
Conversion from Convertible Debentures to Conversion Units [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 4
Debt Conversion, Original Debt, Amount	$ 1,200,000
Debt Conversion, Accrued Interest Amount	$ 14,667
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares	303,668
Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche One [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares	177,626
Number of Common Stock Securities Called by Each Unit (in shares) | shares	1
Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche Two [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares	126,042
June 2020 Warrants [Member]
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares		120,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 5	$ 10			$ 5
Warrants and Rights Outstanding		$ 457,833
Payments of Debt Issuance Costs		$ 161,500
Conversion Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares	1
Pre-Funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.01				$ 0.01		$ 0.01
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares	1						1
Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche Two [Member]
Number of Warrants Called by Each Unit (in shares) | shares	1
Unit Warrants [Member]
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	2,560,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 5
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares	1
Convertible Debentures [Member]
Number of Institutional Investors		2
Proceeds from Convertible Debt, Gross		$ 1,050,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Debt Instrument, Face Amount		$ 1,200,000
Proceeds from Convertible Debt		$ 888,500
Debt Instrument, Term (Year)		12 months
Gross Proceeds from Issuance of Common Stock, Public Offering		$ 6,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares		$ 10
Percentage of Offering Price		80.00%
Debt Instrument, Convertible, Maximum Allowed Ownership of Common Stock Outstanding, Percentage		4.99%
Debt Instrument, Unamortized Discount, Total	$ 645,150	$ 769,334
Debt Conversion, Original Debt Discount		$ 150,000
Interest Expense, Debt, Total					$ 138,851
Amortization of Debt Discount (Premium)					$ 124,185

Note 7 - Commitments (Details T

Note 7 - Commitments (Details Textual)	12 Months Ended
	Dec. 31, 2020USD ($)ft²	Dec. 31, 2019USD ($)	Sep. 30, 2021USD ($)
Area of Real Estate Property (Square Foot) | ft²	8,400
Operating Leases, Rent Expense, Total	$ 166,577	$ 161,673
Lessee, Operating Lease, Liability, to be Paid, Year One	171,213
Lessee, Operating Lease, Liability, to be Paid, Year Two	176,356
Unrecorded Unconditional Purchase Obligation, Total	190,000		$ 607,000
Unrecorded Unconditional Purchase Obligation Reimbursable, Amount	$ 165,500

Note 8 - Stockholders' Equity_2

Note 8 - Stockholders' Equity (Details Textual)	Feb. 11, 2021$ / sharesshares	Sep. 29, 2020USD ($)$ / sharesshares	Sep. 25, 2020	Sep. 24, 2020USD ($)$ / sharesshares	Jan. 21, 2020	Apr. 30, 2019	Apr. 26, 2019USD ($)shares	Feb. 26, 2019USD ($)	Feb. 25, 2019USD ($)	Jul. 31, 2020shares	Jan. 31, 2020USD ($)shares	Jul. 31, 2019USD ($)shares	Feb. 28, 2019shares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Jun. 26, 2020$ / sharesshares
Preferred Stock, Shares Authorized (in shares)																		10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares														$ 0.01		$ 0.01		$ 0.01	$ 0.01
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																		100	2,486
Stock Issued During Period, Shares, New Issues (in shares)	1,644,000
Proceeds from Issuance or Sale of Equity, Gross | $				$ 12,800,000
Proceeds from Issuance or Sale of Equity, Total | $				$ 11,200,000
Number of Common Stock Securities Called by Each Unit (in shares)		1
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 6.25
Deferred Compensation Liability Conversion to Equity, Amount | $		$ 1,500,000
Deferred Compensation Liability Conversion to Equity, Conversion Price (in dollars per share) | $ / shares		$ 5
Stock Issued During Period, Shares, Cancellation of Accrued Compensation (in shares)		300,001
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)		177,626
Stock Issued During Period, Shares, Issued for Services (in shares)																13,707		26,581	162
Stock Issued During Period, Shares, Warrants Exercised (in shares)																		36,902
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent																		110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)																		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)																		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares																		$ 1.12
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																0		602,000	0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $																		$ 655,510
Class of Warrant or Right, Outstanding (in shares)																		3,600,337
Prepaid Expense, Value of Stock Issued for Services During Period | $														$ 39,773		$ 39,773		$ 48,667
Expense Related To Consulting And Investment Banking Agreements [Member]
Share-based Payment Arrangement, Expense | $																		45,733	$ 223,080
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense | $														$ 56,190	$ 0	$ 168,570	$ 0	$ 18,730	$ 104,420
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)																2 years 2 months 12 days		2 years 10 months 24 days
Stock Incentive Plan 2020 [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)														1,500,000		1,500,000		1,000,000
Conversion from Convertible Debentures to Conversion Units [Member]
Debt Conversion, Converted Instrument, Principal and Interest, Amount | $		$ 1,214,667
Conversion Warrants [Member]
Class Of Warrant Or Right, Issued During Period (in shares)				2,560,000
Conversion Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)		303,668
Unit Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 5
Warrants and Rights Outstanding, Term (Year)				5 years
Pre-Funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.01		$ 0.01														$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		250,000
Class of Warrant or Right, Outstanding (in shares)																		126,042
Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)		126,042
Representative Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 6.875			$ 5.50														$ 5.50
Warrants and Rights Outstanding, Term (Year)				3 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	72,000	128,000		128,000
Class of Warrant or Right, Period for Warrants or Rights Exercisable (Day)				180 days
Class of Warrant or Right, Outstanding (in shares)																		128,000
Management Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		300,001
Number of Warrants Called by Each Unit (in shares)		1
Series I Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																		$ 5
Stock Issued During Period, Shares, Warrants Exercised (in shares)										29,755
Class of Warrant or Right, Outstanding (in shares)																		62,626
June 2020 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 5																$ 5		$ 10
Warrants and Rights Outstanding, Term (Year)																				5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																				120,000
Class of Warrant or Right, Outstanding (in shares)																		120,000
Unit Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 5
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		2,560,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			20		2,000	500
Series G Convertible Preferred Stock and Related Warrants [Member]
Convertible Preferred Stock and Related Warrants, Authorized (in shares)													1,000
Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum | $								$ 250,000	$ 1,000,000
Convertible Preferred Stock and Related Warrants Issued (in shares)							500						500
Series G Convertible Preferred Stock [Member]
Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum | $							$ 500,000
Capital Units [Member]
Stock Issued During Period, Shares, New Issues (in shares)				2,560,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares				$ 5
Conversion of Series C Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)																			587
Conversion of Stock, Shares Issued (in shares)																			2
Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)																			1,563
Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)																			1,200
Conversion of Series F Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)																			507
Conversion of Stock, Shares Issued (in shares)																			9
Conversion from Series F Preferred Stock to Series H Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)																			2,256
Conversion of Series H Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)																		1,686	1,570
Conversion of Stock, Shares Issued (in shares)																		469,697	14,808
Conversion of Series I Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)																		700
Conversion of Stock, Shares Issued (in shares)																		204,371
Conversion of Series J Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)																		300
Conversion of Stock, Shares Issued (in shares)																		42,723
Conversion of Series H, Series I, and Series J Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)																		716,790	14,819
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)														10,000,000		10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares														$ 1,000		$ 1,000		$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)														0		0		100	100
Convertible Preferred Stock, Conversion Price1 (in dollars per share) | $ / shares																		$ 7,000,000
Series C Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares																		$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																		0
Series E Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares																		$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																		0
Series F Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																		0
Number of Series C and Series E Preferred Stock Exchanged for Series F Convertible Preferred Stock (in shares)													2,763
Series G Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)												1,000						0
Series H Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																		0	1,686
Conversion of Stock, Shares Issued (in shares)												3,256
Series I Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																		0	700
Stock Issued During Period, Shares, New Issues (in shares)												700
Proceeds from Issuance of Preferred Stock and Preference Stock | $												$ 700,000
Series J Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)																		0
Stock Issued During Period, Shares, New Issues (in shares)											300
Proceeds from Issuance of Preferred Stock and Preference Stock | $											$ 300,000
Capital Units Tranche One [Member] | Capital Units [Member]
Stock Issued During Period, Shares, New Issues (in shares)				2,310,000
Number of Common Stock Securities Called by Each Unit (in shares)				1
Capital Units Tranche Two [Member] | Capital Units [Member]
Stock Issued During Period, Shares, New Issues (in shares)				250,000
Units Including Pre-Funded Warrants [Member] | Capital Units [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares				$ 4.99

Note 8 - Stockholders' Equity -

Note 8 - Stockholders' Equity - Preferred Stock Summary (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Preferred stock, shares outstanding (in shares)		100	2,486
Preferred Stock	$ 0	$ 76,095	$ 1,932,433
Series B Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	0	100	100
Preferred Stock		$ 76,095	$ 76,095
Series H Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)		0	1,686
Preferred Stock		$ 0	$ 1,156,338
Series I Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)		0	700
Preferred Stock		$ 0	$ 700,000

Note 8 - Stockholders' Equity_3

Note 8 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)	12 Months Ended
	Dec. 31, 2020
Weighted average risk-free interest rates	0.69%
Expected dividend yield	0.00%
Expected life of option (Year)	7 years
Expected volatility	38.16%

Note 8 - Stockholders' Equity-

Note 8 - Stockholders' Equity- Stock Option Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Outstanding, shares (in shares)	602,000	0
Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 2.79	$ 2.79	$ 0
Granted, shares (in shares)	0	602,000	0
Granted, Weighted Average Exercise Price (in dollars per share)		$ 2.79
Exercised, shares (in shares)		0
Exercised, Weighted Average Exercise Price (in dollars per share)		$ 0
Forfeited or expired, shares (in shares)		0
Forfeited or expired, Weighted Average Exercise Price (in dollars per share)		$ 0
Outstanding, shares (in shares)	602,000	602,000	0
Outstanding, Weighted Average Remaining Contractual Term (Year)	9 years 2 months 12 days	9 years 10 months 24 days
Outstanding, Intrinsic Value		$ 355,180
Exercisable, shares (in shares)		0
Exercisable, Weighted Average Exercise Price (in dollars per share)		$ 0
Exercisable, Intrinsic Value		$ 0

Note 8 - Stockholders' Equity_4

Note 8 - Stockholders' Equity - Summary of Warrants (Details) - $ / shares	Feb. 11, 2021	Dec. 31, 2020	Sep. 29, 2020	Sep. 24, 2020	Jun. 26, 2020
Number of warrants (in shares)		3,600,337
Weighted Average [Member]
Exercise price (in dollars per share)		$ 4.84
Series I Warrants [Member]
Number of warrants (in shares)		62,626
Exercise price (in dollars per share)		$ 5
June 2020 Warrants [Member]
Number of warrants (in shares)		120,000
Exercise price (in dollars per share)		$ 5	$ 5		$ 10
Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years) (Year)					5 years
Pre-Funded Warrants [Member]
Number of warrants (in shares)		126,042
Exercise price (in dollars per share)		$ 0.01	$ 0.01	$ 0.01
Unit, Conversion and Management Warrants [Member]
Number of warrants (in shares)		3,163,669
Exercise price (in dollars per share)		$ 5
Representative Warrants [Member]
Number of warrants (in shares)		128,000
Exercise price (in dollars per share)	$ 6.875	$ 5.50		$ 5.50
Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years) (Year)				3 years
Outstanding Warrants Excluding Pre-Funded Warrants [Member] | Weighted Average [Member]
Weighted-Average Remaining Life (excluding Pre-Funded Warrants) (years) (Year)		4 years 8 months 12 days

Note 9 - Retirement Plan (Detai

Note 9 - Retirement Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 27,511	$ 25,876

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Income Taxes Paid	$ 0	$ 0
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount		1,200
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total		61,800
Operating Loss Carryforwards, Subject to Expiration		$ 53,600

Note 10 - Income Taxes - Deferr

Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Net operating loss carryforward	$ 14,737,240	$ 15,328,336
Research and development tax credit carryforward	1,189,110	1,122,536
Stock-based compensation expense	4,870	1,877,284
Accrued salaries and directors’ fees	72,721	450,503
Depreciation	0	8,571
Total deferred tax assets	16,003,941	18,787,230
Depreciation	28,274	0
Net deferred tax assets	15,975,667	18,787,230
Valuation allowance	(15,975,667)	(18,787,230)
Net deferred tax asset after reduction for valuation allowance	$ 0	$ 0

Note 10 - Income Taxes - Reconc

Note 10 - Income Taxes - Reconciliation of Income Tax Benefit (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
U.S. federal statutory rate applied to pretax loss	$ (621,194)	$ (497,833)
Permanent differences	65	278
Research and development credits	(66,574)	(47,053)
Change in valuation allowance, net of expired items and other adjustments	687,703	544,308
Reported income tax expense	$ 0	$ 0

Note 11 - Grants and Collabor_2

Note 11 - Grants and Collaboration Revenue (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Revenue from Contract with Customer, Including Assessed Tax	$ 30,414	$ 415,458	$ 220,539	$ 1,572,037	$ 1,823,658	$ 1,175,896
Unused Grant Funds	244,888		244,888		165,500
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 30,414	$ 231,330	$ 220,539	$ 1,186,844	1,438,465	983,682
Research Agreements [Member]
Revenue from Contract with Customer, Including Assessed Tax					$ 385,193	$ 192,214

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($)	Feb. 11, 2021	Aug. 31, 2021	Feb. 28, 2021	Jan. 31, 2021	Jul. 31, 2020	Feb. 28, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Revenue from Contract with Customer, Including Assessed Tax							$ 30,414	$ 415,458	$ 220,539	$ 1,572,037	$ 1,823,658	$ 1,175,896
Stock Issued During Period, Shares, Warrants Exercised (in shares)											36,902
Proceeds from Warrant Exercises		$ 230,000	$ 3,174,156						$ 3,404,156	$ 0	$ 2,500	$ 0
Stock Issued During Period, Shares, New Issues (in shares)	1,644,000
Shares Issued, Price Per Share (in dollars per share)	$ 6.25
Proceeds from Issuance of Common Stock	$ 9,400,000
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)	204,000
Series I Warrants [Member]
Stock Issued During Period, Shares, Warrants Exercised (in shares)					29,755
Subsequent Event [Member]
Proceeds from Warrant Exercises						$ 3,174,156
Stock Issued During Period, Shares, New Issues (in shares)	1,644,000
Shares Issued, Price Per Share (in dollars per share)	$ 6.25
Proceeds from Issuance of Common Stock	$ 9,400,000
Subsequent Event [Member] | Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)	204,000
Subsequent Event [Member] | Series I Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)						62,626
Subsequent Event [Member] | Pre-Funded Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)						126,042
Subsequent Event [Member] | Unit Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)						690,034
Subsequent Event [Member] | Common Stock Warrants [Member]
Stock Issued During Period, Shares, Warrants Exercised (in shares)						835,900
SBIR Grant [Member] | Subsequent Event [Member]
Revenue from Contract with Customer, Including Assessed Tax				$ 299,927

Schedule II - Valuation and Q_3

Schedule II - Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance at Beginning Of Period	$ 18,787,230	$ 19,879,954
Additions Charged to Costs and Expenses	(2,811,563)	(1,092,724)
Additions Charged to Other Accounts	0	0
Deductions	0	0
Balance at End Of Period	$ 15,975,667	$ 18,787,230